Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.

Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS.

Neurosci Biobehav Rev. 2011 Jan;35(3):804-17. doi: 10.1016/j.neubiorev.2010.10.001. Epub 2010 Oct 8. Review.

PMID:
20934453
2.

From neuroprogression to neuroprotection: implications for clinical care.

Berk M, Conus P, Kapczinski F, Andreazza AC, Yücel M, Wood SJ, Pantelis C, Malhi GS, Dodd S, Bechdolf A, Amminger GP, Hickie IB, McGorry PD.

Med J Aust. 2010 Aug 16;193(4 Suppl):S36-40.

PMID:
20712560
3.

Role of oxidative stress in the pathophysiology of bipolar disorder.

Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J.

Neurochem Res. 2010 Sep;35(9):1295-301. doi: 10.1007/s11064-010-0195-2. Epub 2010 May 25. Review.

PMID:
20499165
4.

Mediators of allostasis and systemic toxicity in bipolar disorder.

Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F.

Physiol Behav. 2012 Apr 12;106(1):46-50. doi: 10.1016/j.physbeh.2011.10.029. Epub 2011 Nov 3. Review.

PMID:
22079584
5.

Neuroprogression: pathways to progressive brain changes in bipolar disorder.

Berk M.

Int J Neuropsychopharmacol. 2009 May;12(4):441-5. doi: 10.1017/S1461145708009498. Epub 2008 Oct 16. No abstract available.

PMID:
18922203
6.

The potential use of biomarkers as an adjunctive tool for staging bipolar disorder.

Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vázquez GH, Vieta E, Berk M.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1366-71. doi: 10.1016/j.pnpbp.2009.07.027. Epub 2009 Aug 8.

PMID:
19666076
7.

Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder.

Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN.

Int J Neuropsychopharmacol. 2009 May;12(4):447-58. doi: 10.1017/S1461145708009310. Epub 2008 Sep 4.

PMID:
18771602
8.

Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder.

Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, Colpo GD, Stertz L, Panizzutti B, Magalhães PV, Kapczinski F.

Expert Rev Neurother. 2013 Jul;13(7):827-42. doi: 10.1586/14737175.2013.811981. Review.

PMID:
23898853
9.

Therapeutic use of omega-3 fatty acids in bipolar disorder.

Balanzá-Martínez V, Fries GR, Colpo GD, Silveira PP, Portella AK, Tabarés-Seisdedos R, Kapczinski F.

Expert Rev Neurother. 2011 Jul;11(7):1029-47. doi: 10.1586/ern.11.42. Review.

PMID:
21721919
10.

Staging and neuroprogression in bipolar disorder.

Fries GR, Pfaffenseller B, Stertz L, Paz AV, Dargél AA, Kunz M, Kapczinski F.

Curr Psychiatry Rep. 2012 Dec;14(6):667-75. doi: 10.1007/s11920-012-0319-2. Review.

PMID:
23090632
11.

Sex hormones and biomarkers of neuroprotection and neurodegeneration: implications for female reproductive events in bipolar disorder.

Frey BN, Dias RS.

Bipolar Disord. 2014 Feb;16(1):48-57. doi: 10.1111/bdi.12151. Epub 2013 Nov 11. Review.

PMID:
24206266
12.

The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment.

Andreazza AC, Young LT.

Int J Neuropsychopharmacol. 2014 Jul;17(7):1039-52. doi: 10.1017/S1461145713000096. Epub 2013 Mar 1. Review.

PMID:
23449044
13.

Staging and neuroprogression in bipolar disorder: a systematic review of the literature.

Gama CS, Kunz M, Magalhães PV, Kapczinski F.

Rev Bras Psiquiatr. 2013 Mar;35(1):70-4. Review.

14.

Biomarkers and staging of bipolar disorder: a systematic review.

Roda Â, Chendo I, Kunz M.

Trends Psychiatry Psychother. 2015 Jan-Mar;37(1):3-11. doi: 10.1590/2237-6089-2014-0002. Epub 2014 Dec 9. Review.

15.

Neurochemical underpinnings in bipolar disorder and epilepsy.

Amann B, Grunze H.

Epilepsia. 2005;46 Suppl 4:26-30.

16.

The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications.

Moylan S, Maes M, Wray NR, Berk M.

Mol Psychiatry. 2013 May;18(5):595-606. doi: 10.1038/mp.2012.33. Epub 2012 Apr 24. Review.

PMID:
22525486
17.

The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care and research.

Rizzo LB, Costa LG, Mansur RB, Swardfager W, Belangero SI, Grassi-Oliveira R, McIntyre RS, Bauer ME, Brietzke E.

Neurosci Biobehav Rev. 2014 May;42:157-69. doi: 10.1016/j.neubiorev.2014.02.004. Epub 2014 Feb 15. Review.

PMID:
24548785
18.

Selfish brain and neuroprogression in bipolar disorder.

Mansur RB, Cha DS, Asevedo E, McIntyre RS, Brietzke E.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:66-71. doi: 10.1016/j.pnpbp.2012.12.004. Epub 2012 Dec 20. Review.

PMID:
23266709
19.

Putative neuroprotective agents in neuropsychiatric disorders.

Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:135-45. doi: 10.1016/j.pnpbp.2012.11.007. Epub 2012 Nov 23. Review.

PMID:
23178231
20.

Serum S100B and antioxidant enzymes in bipolar patients.

Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, Cunha AB, Ceresér KM, Santin A, Gottfried C, Salvador M, Kapczinski F, Gonçalves CA.

J Psychiatr Res. 2007 Sep;41(6):523-9. Epub 2006 Sep 7.

PMID:
16956621
Items per page

Supplemental Content

Write to the Help Desk